Investigating biomarkers for heart failure in patients with obesity
Biomarkers in Patients With Suspected Heart Failure With Preserved Ejection Fraction
NHS Greater Glasgow and Clyde · NCT06101693
This study is trying to find better ways to diagnose heart failure in people with obesity by looking at new blood tests and other health information.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1028 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | NHS Greater Glasgow and Clyde (other) |
| Locations | 3 sites (Glasgow and 2 other locations) |
| Trial ID | NCT06101693 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify alternative cut-offs for NT-proBNP and novel biomarkers to better diagnose heart failure with preserved ejection fraction (HFpEF) in patients with suspected heart failure, particularly those with obesity. It will involve a prospective analysis of patients in primary care who have undergone NT-proBNP testing. The study will assess clinical history, patient-reported outcomes, and various diagnostic tests, including echocardiography and biomarker analysis. Participants will be followed for a minimum of 10 years to track hospitalizations and outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with suspected heart failure who have had NT-proBNP testing performed by their primary care physician.
Not a fit: Patients presenting with acute heart failure or those with a previous diagnosis of heart failure may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods for heart failure in obese patients, potentially reducing delayed diagnoses and adverse outcomes.
How similar studies have performed: While there is ongoing research in this area, the specific approach of identifying novel biomarkers in obese patients with suspected HFpEF is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Written informed consent * Age ≥ 18 years * NT-proBNP sample taken by primary care physician as part of routine care for suspected heart failure Exclusion Criteria: * Unable to consent to inclusion in study due to significant cognitive impairment * Geographical/ social reasons preventing attending study centre * Unable to complete study assessments * Patients presenting with acute HF or a previous diagnosis of HF
Where this trial is running
Glasgow and 2 other locations
- Glasgow Royal Infirmary — Glasgow, United Kingdom (RECRUITING)
- New Victoria Hospital — Glasgow, United Kingdom (RECRUITING)
- Queen Elizabeth University Hospital — Glasgow, United Kingdom (RECRUITING)
Study contacts
- Principal investigator: Ross Campbell, MBChB — University of Glasgow
- Study coordinator: Ross Campbell, MBChB
- Email: ross.campbell@glasgow.ac.uk
- Phone: 01413302418
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Heart Failure, Obesity, Heart Failure With Preserved Ejection Fraction